Solid financial performance:
- €128 million in operating income before non-recurring items, up 6.5%
- Strong increase in cash flow
Faster expansion in emerging markets:
- India: acquisition of molecular biology specialist RAS
- Emerging 7*: organic sales growth of 24%
- bioMérieux China: now the Group’s third largest company